Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Meera, Tugnait"'
Autor:
Michael J. Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 4, Pp 624-637 (2024)
Abstract Brigatinib is an oral anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK‐positive metastatic non‐small cell lung cancer. In vitro studies indicated that brigatinib is primarily metabolized by CYP2C8 and CYP3A4 a
Externí odkaz:
https://doaj.org/article/f60485c9b0764388b669749419b519e4
Autor:
Yoon-Koo Kang, Beni B. Wolf, Hongliang Shi, Klaus P. Hoeflich, Oleg Schmidt-Kittler, Cori Ann Sherwin, Christoph Lengauer, Nancy E. Kohl, Margit Hagel, Nicolas Stransky, Meera Tugnait, Melissa Manoogian, Josep M. Llovet, Daniel H. Palmer, Jean-Francois Dufour, Chia-Jui Yen, Lynn G. Feun, Sandrine Faivre, Stephen L. Chan, Zhong-Zhe Lin, Sunil Sharma, Jung-Hwan Yoon, Andrew X. Zhu, Joerg Trojan, Vincenzo Mazzaferro, Ho-Yeong Lim, Max W. Sung, Antoine Hollebecque, Su Pin Choo, Joong-Won Park, Teresa Macarulla, Thomas Yau, Tim Meyer, Debashis Sarker, Richard D. Kim
Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5358f74ce70ebf2806694a47d8bf6671
https://doi.org/10.1158/2159-8290.22536304
https://doi.org/10.1158/2159-8290.22536304
Autor:
Yoon-Koo Kang, Beni B. Wolf, Hongliang Shi, Klaus P. Hoeflich, Oleg Schmidt-Kittler, Cori Ann Sherwin, Christoph Lengauer, Nancy E. Kohl, Margit Hagel, Nicolas Stransky, Meera Tugnait, Melissa Manoogian, Josep M. Llovet, Daniel H. Palmer, Jean-Francois Dufour, Chia-Jui Yen, Lynn G. Feun, Sandrine Faivre, Stephen L. Chan, Zhong-Zhe Lin, Sunil Sharma, Jung-Hwan Yoon, Andrew X. Zhu, Joerg Trojan, Vincenzo Mazzaferro, Ho-Yeong Lim, Max W. Sung, Antoine Hollebecque, Su Pin Choo, Joong-Won Park, Teresa Macarulla, Thomas Yau, Tim Meyer, Debashis Sarker, Richard D. Kim
Outcomes for patients with advanced hepatocellular carcinoma (HCC) remain poor despite recent progress in drug development. Emerging data implicate FGF19 as a potential HCC driver, suggesting its receptor, FGFR4, as a novel therapeutic target. We eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3420a193e786a9c83eca685a72671237
https://doi.org/10.1158/2159-8290.c.6548104.v1
https://doi.org/10.1158/2159-8290.c.6548104.v1
Autor:
Daniel J. DeAngelo, Deepti H. Radia, Tracy I. George, William A. Robinson, Albert T. Quiery, Mark W. Drummond, Prithviraj Bose, Elizabeth O. Hexner, Elliott Winton, Hans-Peter Horny, Meera Tugnait, Hui-Min Lin, Saša Dimitrijević, Javier I. Munoz-Gonzalez, Ilda Bidollari, Michael W. Deininger, Jason Gotlib
Publikováno v:
Blood. 140:3932-3934
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b35842025a9abe675ca052303fde0d6
https://doi.org/10.1182/blood-2022-167593
https://doi.org/10.1182/blood-2022-167593
Autor:
Daniel J. DeAngelo, Deepti H. Radia, Tracy I. George, William A. Robinson, Albert T. Quiery, Mark W. Drummond, Prithviraj Bose, Elizabeth O. Hexner, Elliott F. Winton, Hans-Peter Horny, Meera Tugnait, Oleg Schmidt-Kittler, Erica K. Evans, Hui-Min Lin, Brenton G. Mar, Srdan Verstovsek, Michael W. Deininger, Jason Gotlib
Publikováno v:
Nature Medicine. 27:2183-2191
Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) evaluated avapritinib (BLU-285), a selective KIT D816V inhibitor, in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c703208f8e6b00722bf2b7551912df50
https://doi.org/10.1038/s41591-021-01538-9
https://doi.org/10.1038/s41591-021-01538-9
Autor:
David Kerstein, Meera Tugnait, Michael J. Hanley, Neeraj Gupta, Karthik Venkatakrishnan, Narayana I. Narasimhan, Thomas Marbury
Publikováno v:
Investigational New Drugs
SummaryBackground Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, targets activated, mutant forms of ALK and overcomes mechanisms of resistance to the ALK inhibitors crizotinib, ceritinib, and alectinib. Brigatinib is approv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2879e63266320f973b7978db5034a636
https://doi.org/10.1007/s10637-021-01095-5
https://doi.org/10.1007/s10637-021-01095-5
Autor:
William D. Tap, Sebastian Bauer, Beni B. Wolf, Meera Tugnait, Robin L. Jones, Sant P. Chawla, Olivier Mir, Piotr Rutkowski, Tamieka Lauz, Ferry A.L.M. Eskens, Teresa Zhou, Jonathan C. Trent, Margaret von Mehren, Suzanne George, Erica Evans, César Serrano, Patrick Schöffski, Michael Heinrich, Philippe A. Cassier, Maria Roche, Yoon-Koo Kang
Publikováno v:
Lancet Oncology, 21(7), 935-946. Lancet Publishing Group
Summary Background Targeting of KIT and PDGFRA with imatinib revolutionised treatment in gastrointestinal stromal tumour; however, PDGFRA Asp842Val (D842V)-mutated gastrointestinal stromal tumour is highly resistant to tyrosine kinase inhibitors. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9845ef51513e327425b820d8113203a3
https://doi.org/10.1016/s1470-2045(20)30269-2
https://doi.org/10.1016/s1470-2045(20)30269-2
Autor:
Wei-Sheng, Huang, Feng, Li, Yongjin, Gong, Yun, Zhang, Willmen, Youngsaye, Yongjin, Xu, Xiaotian, Zhu, Matthew T, Greenfield, Anna, Kohlmann, Paul M, Taslimi, Angela, Toms, Stephan G, Zech, Tianjun, Zhou, Biplab, Das, Hyun G, Jang, Meera, Tugnait, Yihua E, Ye, Francois, Gonzalvez, Theresa E, Baker, Sara, Nadworny, Yaoyu, Ning, Scott D, Wardwell, Sen, Zhang, Alexandra E, Gould, Yongbo, Hu, Weston, Lane, Robert J, Skene, Hua, Zou, Tim, Clackson, Narayana I, Narasimhan, Victor M, Rivera, David C, Dalgarno, William C, Shakespeare
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 80:129084
In the treatment of non-small cell lung cancer (NSCLC), patients harboring exon 20 insertion mutations in the epidermal growth factor receptor (EGFR) gene (EGFR) have few effective therapies because this subset of mutants is generally resistant to mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36257c29b5ae4b54e2d345df53177fd7
https://doi.org/10.1016/j.bmcl.2022.129084
https://doi.org/10.1016/j.bmcl.2022.129084
Autor:
Vincenzo Mazzaferro, Jung Hwan Yoon, Chia Jui Yen, Sunil Sharma, Max Sung, Josep M. Llovet, Tim Meyer, Meera Tugnait, Sandrine Faivre, Stephen L. Chan, Antoine Hollebecque, Daniel H. Palmer, Christoph Lengauer, Teresa Macarulla, Margit Hagel, Ho Yeong Lim, Joong-Won Park, Su Pin Choo, Andrew X. Zhu, Lynn G. Feun, Cori Ann Sherwin, Debashis Sarker, Thomas Yau, Melissa Manoogian, Yoon-Koo Kang, Hongliang Shi, Oleg Schmidt-Kittler, Nicolas Stransky, Zhong Zhe Lin, Beni B. Wolf, Nancy E. Kohl, Richard D. Kim, Jean-François Dufour, Joerg Trojan, Klaus P. Hoeflich
Publikováno v:
Cancer Discovery. 9:1696-1707
Outcomes for patients with advanced hepatocellular carcinoma (HCC) remain poor despite recent progress in drug development. Emerging data implicate FGF19 as a potential HCC driver, suggesting its receptor, FGFR4, as a novel therapeutic target. We eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2f1e6cb62e4ffdce43f4c7bcb80434d
https://doi.org/10.1158/2159-8290.cd-19-0555
https://doi.org/10.1158/2159-8290.cd-19-0555
Autor:
Daryl Sonnichsen, Michael J. Hanley, Meera Tugnait, Karthik Venkatakrishnan, David J. Dorer, Neeraj Gupta, Narayana I. Narasimhan, David Kerstein
Publikováno v:
Clinical Pharmacology in Drug Development
In vitro data support involvement of cytochrome P450 (CYP)2C8 and CYP3A4 in the metabolism of the anaplastic lymphoma kinase inhibitor brigatinib. A 3‐arm, open‐label, randomized, single‐dose, fixed‐sequence crossover study was conducted to c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51227ab178a466ce64608e54d9e1c829
https://doi.org/10.1002/cpdd.723
https://doi.org/10.1002/cpdd.723